Three Promising Biotechs Hobbled By First-Impression Issues

We'd all like to think that investment in a particular company is the result of a thorough due diligence process in which we sort out all the issues surrounding an equity by applying the powers of our own analytical abilities to arrive at reasonable investment conclusions. But the sad fact is that most of the money we make in this sector comes at the expense of those who act on impulse alone. Think about it! When our company's Phase 3 pivotal study reads out successfully, we all look forward to that intraday 50-90% gain to offload a few, or all, of our shares. We also realize that the height of that gain will be short-lived. So who are these people buying at the pinnacle of that price pulse?

Hey, check out all the research scientist jobs. Post your resume today!

Back to news